• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miRNAs 作为卵巢癌肿瘤微环境中免疫细胞的调节因子。

MiRNAs as Regulators of Immune Cells in the Tumor Microenvironment of Ovarian Cancer.

机构信息

Department of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Health Center-Research Institute, 281/289 Rzgowska Str., 93-338 Lodz, Poland.

Department of Gynecological Surgery and Gynecological Oncology, Medical University of Lodz, 4 Kosciuszki Str., 90-419 Lodz, Poland.

出版信息

Cells. 2024 Aug 13;13(16):1343. doi: 10.3390/cells13161343.

DOI:10.3390/cells13161343
PMID:39195233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11352322/
Abstract

Ovarian cancer is one of the leading causes of cancer deaths among women. There is an ongoing need to develop new biomarkers and targeted therapies to improve patient outcomes. One of the most critical research areas in ovarian cancer is identifying tumor microenvironment (TME) functions. TME consists of tumor-infiltrating immune cells, matrix, endothelial cells, pericytes, fibroblasts, and other stromal cells. Tumor invasion and growth depend on the multifactorial crosstalk between tumor cells and immune cells belonging to the TME. MiRNAs, which belong to non-coding RNAs that post-transcriptionally control the expression of target genes, regulate immune responses within the TME, shaping the landscape of the intrinsic environment of tumor cells. Aberrant expression of miRNAs may lead to the pathological dysfunction of signaling pathways or cancer cell-regulatory factors. Cell-to-cell communication between infiltrating immune cells and the tumor may depend on exosomes containing multiple miRNAs. MiRNAs may exert both immunosuppressive and immunoreactive responses, which may cause cancer cell elimination or survival. In this review, we highlighted recent advances in the field of miRNAs shaping the landscape of immune cells in the TME.

摘要

卵巢癌是导致女性癌症死亡的主要原因之一。目前仍需要开发新的生物标志物和靶向治疗方法,以改善患者的预后。卵巢癌最重要的研究领域之一是确定肿瘤微环境 (TME) 的功能。TME 由肿瘤浸润免疫细胞、基质、内皮细胞、周细胞、成纤维细胞和其他基质细胞组成。肿瘤的侵袭和生长依赖于肿瘤细胞与属于 TME 的免疫细胞之间的多因素串扰。miRNA 属于非编码 RNA,可在后转录水平上控制靶基因的表达,调节 TME 中的免疫反应,塑造肿瘤细胞固有环境的景观。miRNA 的异常表达可能导致信号通路或癌细胞调节因子的病理性功能障碍。浸润免疫细胞与肿瘤之间的细胞间通讯可能依赖于含有多种 miRNA 的外泌体。miRNA 可能发挥免疫抑制和免疫反应作用,从而导致癌细胞的消除或存活。在这篇综述中,我们强调了 miRNA 领域的最新进展,这些进展塑造了 TME 中免疫细胞的景观。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95f8/11352322/ef899d581af5/cells-13-01343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95f8/11352322/ef899d581af5/cells-13-01343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95f8/11352322/ef899d581af5/cells-13-01343-g001.jpg

相似文献

1
MiRNAs as Regulators of Immune Cells in the Tumor Microenvironment of Ovarian Cancer.miRNAs 作为卵巢癌肿瘤微环境中免疫细胞的调节因子。
Cells. 2024 Aug 13;13(16):1343. doi: 10.3390/cells13161343.
2
Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype.缺氧上皮性卵巢癌细胞来源的外泌体将 microRNAs 递送至巨噬细胞并引发促进肿瘤的表型。
Cancer Lett. 2018 Oct 28;435:80-91. doi: 10.1016/j.canlet.2018.08.001. Epub 2018 Aug 8.
3
Research progress on anti-ovarian cancer mechanism of miRNA regulating tumor microenvironment.miRNA 调控肿瘤微环境抗卵巢癌作用机制的研究进展
Front Immunol. 2022 Nov 10;13:1050917. doi: 10.3389/fimmu.2022.1050917. eCollection 2022.
4
Crosstalk of Exosomal Non-Coding RNAs in The Tumor Microenvironment: Novel Frontiers.外泌体非编码 RNA 在肿瘤微环境中的串扰:新前沿。
Front Immunol. 2022 May 19;13:900155. doi: 10.3389/fimmu.2022.900155. eCollection 2022.
5
microRNAs as biomarkers of ovarian cancer.微小 RNA 作为卵巢癌的生物标志物。
Expert Rev Anticancer Ther. 2020 May;20(5):373-385. doi: 10.1080/14737140.2020.1760095. Epub 2020 May 3.
6
The role of microRNAs in the gastric cancer tumor microenvironment.微小 RNA 在胃癌肿瘤微环境中的作用。
Mol Cancer. 2024 Aug 20;23(1):170. doi: 10.1186/s12943-024-02084-x.
7
MicroRNAs: Pleiotropic Regulators in the Tumor Microenvironment.微小 RNA:肿瘤微环境中的多效调节因子。
Front Immunol. 2018 Nov 1;9:2491. doi: 10.3389/fimmu.2018.02491. eCollection 2018.
8
Role of miRNAs in cell signaling of cancer associated fibroblasts.miRNAs 在癌症相关成纤维细胞细胞信号转导中的作用。
Int J Biochem Cell Biol. 2018 Aug;101:94-102. doi: 10.1016/j.biocel.2018.05.015. Epub 2018 May 25.
9
Dynamic and functional analyses of exosomal miRNAs regulating cellular microenvironment of ovarian cancer cells.调节卵巢癌细胞细胞微环境的外泌体微小RNA的动态与功能分析
J Ovarian Res. 2025 Feb 10;18(1):25. doi: 10.1186/s13048-025-01608-3.
10
MicroRNAs in the Tumor Microenvironment.肿瘤微环境中的 microRNAs。
Adv Exp Med Biol. 2020;1277:1-31. doi: 10.1007/978-3-030-50224-9_1.

引用本文的文献

1
Lifestyle factors affecting the prognosis of gynecological cancer: systematic review and meta-analysis.影响妇科癌症预后的生活方式因素:系统评价与荟萃分析
Cancer Causes Control. 2025 Aug 26. doi: 10.1007/s10552-025-02059-3.
2
MicroRNAs in Cancer Immunology: Master Regulators of the Tumor Microenvironment and Immune Evasion, with Therapeutic Potential.癌症免疫学中的微小RNA:肿瘤微环境和免疫逃逸的主要调节因子,具有治疗潜力。
Cancers (Basel). 2025 Jun 27;17(13):2172. doi: 10.3390/cancers17132172.
3
Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer.

本文引用的文献

1
Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy.免疫疗法与卵巢癌微环境:探索增强治疗效果的潜在策略。
Immunology. 2024 Sep;173(1):14-32. doi: 10.1111/imm.13793. Epub 2024 Apr 15.
2
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth.Let-7i 增强抗肿瘤免疫并抑制卵巢肿瘤生长。
Cancer Immunol Immunother. 2024 Mar 30;73(5):80. doi: 10.1007/s00262-024-03674-w.
3
Role of SLC7A11/xCT in Ovarian Cancer.SLC7A11/xCT 在卵巢癌中的作用。
自然杀伤细胞衍生的外泌体:改变侵袭性乳腺癌的免疫疗法。
Med Oncol. 2025 Mar 18;42(4):114. doi: 10.1007/s12032-025-02647-y.
4
Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs.膀胱癌中的表观遗传修饰:DNA甲基化与微小RNA之间的相互作用
Front Immunol. 2025 Feb 5;16:1518144. doi: 10.3389/fimmu.2025.1518144. eCollection 2025.
Int J Mol Sci. 2024 Jan 2;25(1):587. doi: 10.3390/ijms25010587.
4
miR-124 delivered by BM-MSCs-derived exosomes targets MCT1 of tumor-infiltrating Treg cells and improves ovarian cancer immunotherapy.骨髓间充质干细胞来源的外泌体递送的 miR-124 靶向肿瘤浸润性 Treg 细胞中的 MCT1,改善卵巢癌免疫治疗。
Neoplasma. 2023 Dec;70(6):713-721. doi: 10.4149/neo_2023_230711N362. Epub 2023 Nov 15.
5
miR-146a inhibits ovarian tumor growth via targeting immunosuppressive neutrophils and enhancing CD8 T cell infiltration.微小RNA-146a通过靶向免疫抑制性中性粒细胞并增强CD8 + T细胞浸润来抑制卵巢肿瘤生长。
Mol Ther Oncolytics. 2023 Sep 13;31:100725. doi: 10.1016/j.omto.2023.09.001. eCollection 2023 Dec 19.
6
MicroRNA-211 Regulates Proliferation, Expansion, and Immune Inhibitory Function of Myeloid-Derived Suppressor Cells via Mediation of CHOP Expression.MicroRNA-211 通过调控 CHOP 表达调节髓源性抑制细胞的增殖、扩增和免疫抑制功能。
Immunol Invest. 2023 Nov;52(5):616-634. doi: 10.1080/08820139.2023.2217843. Epub 2023 Jun 13.
7
Extracellular Vesicle-Packaged circATP2B4 Mediates M2 Macrophage Polarization via miR-532-3p/SREBF1 Axis to Promote Epithelial Ovarian Cancer Metastasis.细胞外囊泡包裹的 circATP2B4 通过 miR-532-3p/SREBF1 轴介导线粒体 ATP 敏感性钙通道 2B4 环状 RNA 促进 M2 型巨噬细胞极化进而促进卵巢上皮性癌细胞转移
Cancer Immunol Res. 2023 Feb 3;11(2):199-216. doi: 10.1158/2326-6066.CIR-22-0410.
8
Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis.奥拉帕利治疗晚期卵巢癌的疗效和安全性:一项荟萃分析。
J Obstet Gynaecol. 2023 Dec;43(1):2151883. doi: 10.1080/01443615.2022.2151883. Epub 2022 Dec 9.
9
Research progress on anti-ovarian cancer mechanism of miRNA regulating tumor microenvironment.miRNA 调控肿瘤微环境抗卵巢癌作用机制的研究进展
Front Immunol. 2022 Nov 10;13:1050917. doi: 10.3389/fimmu.2022.1050917. eCollection 2022.
10
Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis.M2 极化肿瘤相关巨噬细胞来源的细胞外囊泡通过 NEAT1/miR-101-3p/ZEB1/PD-L1 轴促进卵巢癌中的免疫逃逸。
Cancer Immunol Immunother. 2023 Mar;72(3):743-758. doi: 10.1007/s00262-022-03305-2. Epub 2022 Nov 1.